Anti-SARS-CoV-2 S-RBD protein Human IgG ELISA Kit KE30003 from Proteintech Group Inc

Product Specs
ItemAnti-SARS-CoV-2 S-RBD protein Human IgG ELISA Kit
CompanyProteintech Group Inc
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberKE30003
ApplicationsELISA
Quantity1 X 96 well plate
Assay Time1.5H
Sample TypeSerum, Plasma
NCBI Gene Aliasesspike glycoprotein
Detection TargetSARS-CoV-2 S-RBD protein

Add to Compare List

Proteintech Group Inc

5500 Pearl Street, Suite 400

Rosemont,, Illinois 60018

United States

Phone: 1-888-478-4522

Email: proteintech@ptglab.com

Company Profile

Website: http://www.ptglab.com

(1) Antibody responses to mRNA versus non-mRNA COVID vaccines among the Mongolian populationIJID RegSeptember 1, 2023Sereejav E, Sandagdorj A, Bazarjav P, Ganbold S, Enkhtuvshin A, Tsedenbal N, Namuuntsetseg B, Chimedregzen K, Badarch D, Otgonbayar D, et al.

(2) Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccinesJournal of medical virologyMarch 1, 2023Yi X, Wang Y, Li Q, Li X, Zhang P, Fu X, Gu S, Zhang D, Liu X, Lou H, et al.

(3) PD-1(high)CXCR5(-)CD4(+) peripheral helper T cells promote CXCR3(+) plasmablasts in human acute viral infectionCell reportsJanuary 31, 2023Asashima H, Mohanty S, Comi M, Ruff WE, Hoehn KB, Wong P, Klein J, Lucas C, Cohen I, Coffey S, et al.Human SARS-CoV-2 Spike (Trimer) IgG ELISA Kit,Thermofisher,BMS2324 Anti-SARS-CoV-2 S-RBD protein Human IgG ELISA Kit,Proteintech,KE30003 Anti-SARS-CoV-2 S-RBD protein Human IgM ELISA Kit,Proteintech,KE30004 LEGENDplex™ SARS-CoV-2 Neut.

(4) Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster doseFrontiers in immunologyJanuary 1, 2023Perico L, Todeschini M, Casiraghi F, Mister M, Pezzotta A, Peracchi T, Tomasoni S, Trionfini P, Benigni A, Remuzzi G.the RBD of the spike protein of SARS-CoV-2 were measured using a quantitative ELISA (Proteintech, #KE30003). Briefly, serum samples diluted 1:200 were incubated on 96-microwell plates pre-coated with recombinant

(5) Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosisFrontiers in immunologyJanuary 1, 2023Cao H, Huang Y, Zhong C, Liao X, Tan W, Zhao S, Guo L, Fan R.the RBD of the SARS-CoV-2 spike protein (anti-S-RBD IgG) according to the manufacturer’s protocol (KE30003; Proteintech, Wuhan, China). Standard and diluted samples were added into microwells (100 µl per well),

(6) Longitudinal Analyses after COVID-19 Recovery or Prolonged Infection Reveal Unique Immunological Signatures after Repeated VaccinationsVaccinesOctober 28, 2022Hisamatsu D, Ikeda A, Ito L, Matsushita Y, Hiki M, Mori H, Tabe Y, Naito T, Akazawa C.

(7) Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational studyBreast cancer research and treatmentOctober 1, 2022Terada M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Uemoto Y, Akiko Kato, Yamanaka N, Sugiura H, et al.

(8) Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2Journal of clinical laboratory analysisJuly 1, 2022Watanabe Y, Matsuba I, Watanabe K, Kunishima T, Takechi Y, Takuma T, Araki Y, Hirotsu N, Sakai H, Oikawa R, et al.

(9) Antibody response of smokers to the COVID-19 vaccination: Evaluation based on cigarette dependenceDrug discoveries & therapeuticsMay 17, 2022Mori Y, Tanaka M, Kozai H, Hotta K, Aoyama Y, Shigeno Y, Aoike M, Kawamura H, Tsurudome M, Ito M.

(10) Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adultsFrontiers of medicineFebruary 1, 2022Zhang Y, Yang Y, Qiao N, Wang X, Ding L, Zhu X, Liang Y, Han Z, Liu F, Zhang X, et al.

(11) An Integrated Platform for Serological Detection and Vaccination of COVID-19Frontiers in immunologyJanuary 1, 2021Wei SC, Hsu WT, Chiu CH, Chang FY, Lo HR, Liao CY, Yang HI, Chou YC, Tsai CH, Chao YC.(Abclonal, Catalog No. RK04138, Woburn, MA, USA), and RBD-protein-based ELISA kit (Proteintech, Catalog No. KE30003, Rosemont, IL, USA). Determination by each kit was performed according to the manufacturer’s procedures

(12) Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infectionFrontiers of medicineDecember 1, 2020Tan Y, Liu F, Xu X, Ling Y, Huang W, Zhu Z, Guo M, Lin Y, Fu Z, Liang D, et al.(RBD) of S-protein and N-protein were detected with anti-SARSCoV-2 S-RBD protein Human IgG ELISA Kit (KE30003, ProteinTech, Rosemont, IL, USA) and anti-SARS-CoV-2 N protein Human IgG ELISA Kit (KE30001, ProteinTech) according

Be the First to Write a Review!

Anti-SARS-CoV-2 S-RBD protein Human IgG ELISA Kit from Proteintech Group Inc

Proteintech Group Inc

Citations (12)

Reviews

Anti-SARS-CoV-2 S-RBD protein Human IgG ELISA Kit from Proteintech Group Inc

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map